Lilly Italia closes 2016 with double-figure growth and continues to invest

Lilly Italia has closed 2016 with a turnover of 852 million euros (up 14% on 2015), generated by the production of insulin (154 million cartridges) and dulaglutide auto-injectors (14 million in 2016, 20 million expected this year, equivalent to 50% of global demand) for patients with type 2 diabetes.

Part of the US pharmaceutical multinational (revenues of US $21.2 billion in 2016), the company also stepped up (from 50 to 70 million euros) the investments it is planning for the model factory in Sesto Fiorentino (Florence), following the signing of a letter of intent in June 2014 as part of a complex urban planning and real estate operation.

When completed, the operation will add a further 70 jobs to the 700 estimated by the end of the year (a total of 670 people currently work at Sesto Fiorentino facility, including 110 hired in 2016).